CoChat

Complement Inhibition Promotes Endogenous Neurogenesis and Sustained Anti-Inflammatory Neuroprotection following Reperfused Stroke

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND PURPOSE: The restoration of blood-flow following cerebral ischemia incites a series of deleterious cascades that exacerbate neuronal injury. Pharmacologic inhibition of the C3a-receptor ameliorates cerebral injury by attenuating post-ischemic inflammation. Recent reports also implicate C3a in the modulation of tissue repair, suggesting that complement may influence both injury and recovery at later post-ischemic time-points. METHODS: To evaluate the effect of C3a-receptor antagonism on post-ischemic neurogenesis and neurological outcome in the subacute period of stroke, transient focal cerebral ischemia was induced in adult male C57BL/6 mice treated with multiple regimens of a C3a receptor antagonist (C3aRA). RESULTS: Low-dose C3aRA administration during the acute phase of stroke promotes neuroblast proliferation in the subventricular zone at 7 days. Additionally, the C3a receptor is expressed on T-lymphocytes within the ischemic territory at 7 days, and this cellular infiltrate is abrogated by C3aRA administration. Finally, C3aRA treatment confers robust histologic and functional neuroprotection at this delayed time-point. CONCLUSIONS: Targeted complement inhibition through low-dose antagonism of the C3a receptor promotes post-ischemic neuroblast proliferation in the SVZ. Furthermore, C3aRA administration suppresses T-lymphocyte infiltration and improves delayed functional and histologic outcome following reperfused stroke. Post-ischemic complement activation may be pharmacologically manipulated to yield an effective therapy for stroke.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0038664

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 High-dose C3aRA suppresses basal neurogenesis in the SVZ relative to a low-dose regimen. Basal neurogenesis in the SVZ depicted by representative immunostaining of the SVZ of animals treated for 10 days with vehicle, low dose (1 mg/kg/day) and high dose (40 mg/kg/day) of C3aRA. BrdU staining is represented in green, DCx staining in red, and co-localized cells appear yellow. Images are representative of findings from at least 4 animals per experiment. Scale bar = 120 µm (A). Representative low-power immunostain of a coronal section depicting the anatomic relationships between the SVZ, the striatum (ST) and lateral ventricle (LV). BrdU staining is represented in green and DCx staining in red. Scale bar = 120 µm (B). Decreased BrdU+ cells (p = 0.01*) were observed in the SVZ in the high-dose cohort (n = 10 per cohort) relative to vehicle (C). BrdU and DCX co-localized cell counts in the SVZ were also suppressed (p = 0.05*) with high-dose treatment relative to vehicle (n = 10 per cohort) (D).
Figure 1 High-dose C3aRA suppresses basal neurogenesis in the SVZ relative to a low-dose regimen. Basal neurogenesis in the SVZ depicted by representative immunostaining of the SVZ of animals treated for 10 days with vehicle, low dose (1 mg/kg/day) and high dose (40 mg/kg/day) of C3aRA. BrdU staining is represented in green, DCx staining in red, and co-localized cells appear yellow. Images are representative of findings from at least 4 animals per experiment. Scale bar = 120 µm (A). Representative low-power immunostain of a coronal section depicting the anatomic relationships between the SVZ, the striatum (ST) and lateral ventricle (LV). BrdU staining is represented in green and DCx staining in red. Scale bar = 120 µm (B). Decreased BrdU+ cells (p = 0.01*) were observed in the SVZ in the high-dose cohort (n = 10 per cohort) relative to vehicle (C). BrdU and DCX co-localized cell counts in the SVZ were also suppressed (p = 0.05*) with high-dose treatment relative to vehicle (n = 10 per cohort) (D).CC BY · PubMed Central
Figure 2 Reperfused stroke stimulates the proliferation of migrating neuroblasts in the SVZ at 7 days post-ischemia. Representative high-power split-channel immunostain of the SVZ at 7 days post-reperfusion for BrdU (green) and DCx (red), demonstrating robust co-localization (yellow) of these proteins. Scale bar = 40 µm.
Figure 2 Reperfused stroke stimulates the proliferation of migrating neuroblasts in the SVZ at 7 days post-ischemia. Representative high-power split-channel immunostain of the SVZ at 7 days post-reperfusion for BrdU (green) and DCx (red), demonstrating robust co-localization (yellow) of these proteins. Scale bar = 40 µm.CC BY · PubMed Central
Figure 3 Acute C3aRA administration promotes post-ischemic neurogenesis in the SVZ. The effect of C3aR antagonism on the extent of ischemia-induced neurogenesis in the SVZ at 7 days post-reperfusion was assessed by immunostaining for both DCx and BrdU. Analysis of stereological cell-counts in the ipsilateral and contralateral SVZ revealed significant differences between treatment groups. Animals in the acute treatment cohort demonstrated significant increases (p<0.05) of DCx+ cells in the contralateral SVZ relative to both vehicle and delayed treatment cohorts (vehicle: n = 12, acute: n = 18, combined: n = 14, delayed: n = 14) (A). No significant differences in the total BrdU+ count were observed either in the ipsilateral or contralateral SVZ (vehicle: n = 12, acute: n = 18, combined: n = 14, delayed: n = 14) (B). DCx/BrdU co-localized cells were significantly increased (p<0.05) in the acute treatment cohort relative to both vehicle and delayed cohorts (vehicle: n = 12, acute: n = 18, combined: n = 14, delayed: n = 14). (C). This comparison was significant in both ipsilateral and contralateral SVZ.
Figure 3 Acute C3aRA administration promotes post-ischemic neurogenesis in the SVZ. The effect of C3aR antagonism on the extent of ischemia-induced neurogenesis in the SVZ at 7 days post-reperfusion was assessed by immunostaining for both DCx and BrdU. Analysis of stereological cell-counts in the ipsilateral and contralateral SVZ revealed significant differences between treatment groups. Animals in the acute treatment cohort demonstrated significant increases (p<0.05) of DCx+ cells in the contralateral SVZ relative to both vehicle and delayed treatment cohorts (vehicle: n = 12, acute: n = 18, combined: n = 14, delayed: n = 14) (A). No significant differences in the total BrdU+ count were observed either in the ipsilateral or contralateral SVZ (vehicle: n = 12, acute: n = 18, combined: n = 14, delayed: n = 14) (B). DCx/BrdU co-localized cells were significantly increased (p<0.05) in the acute treatment cohort relative to both vehicle and delayed cohorts (vehicle: n = 12, acute: n = 18, combined: n = 14, delayed: n = 14). (C). This comparison was significant in both ipsilateral and contralateral SVZ.CC BY · PubMed Central
Figure 4 C3aR is robustly expressed on the surface of CD3+ cells in the ischemic region. C3aR is not expressed on cells in the SVZ at 24 hours post-MCAO. Immunostaining of the SVZ at 24 hours and 7 days post-MCAO reveals several migrating neuroblasts (DCx+, green) without any significant C3aR immunopositivity (red) (A). Images are representative of findings from at least 4 animals per experiment. Scale bars = 75 µm. Examination of the infarct border at 7 days at low-power reveals a massive influx of cells bearing C3a receptor (red) in the region of the infarct, counterstained with Nissl (blue), depicted by a loss of MAP2 staining (green) (B). Scale bars = 170 µm. Higher-power images in the region of the infarct more clearly demonstrate cells bearing C3aR (red), many of which demonstrate robust expression of CD3 (green) (C). Merged channels depict unequivocal co-localization of C3aR with CD3 (yellow) in the majority of cells observed. Scale bars = 75 µm.
Figure 4 C3aR is robustly expressed on the surface of CD3+ cells in the ischemic region. C3aR is not expressed on cells in the SVZ at 24 hours post-MCAO. Immunostaining of the SVZ at 24 hours and 7 days post-MCAO reveals several migrating neuroblasts (DCx+, green) without any significant C3aR immunopositivity (red) (A). Images are representative of findings from at least 4 animals per experiment. Scale bars = 75 µm. Examination of the infarct border at 7 days at low-power reveals a massive influx of cells bearing C3a receptor (red) in the region of the infarct, counterstained with Nissl (blue), depicted by a loss of MAP2 staining (green) (B). Scale bars = 170 µm. Higher-power images in the region of the infarct more clearly demonstrate cells bearing C3aR (red), many of which demonstrate robust expression of CD3 (green) (C). Merged channels depict unequivocal co-localization of C3aR with CD3 (yellow) in the majority of cells observed. Scale bars = 75 µm.CC BY · PubMed Central
Figure 5 Antagonism of the C3aR provides sustained histologic neuroprotection. Infarct volume was determined by integrating serial coronal H&E stained sections. Significantly decreased volume of subcortical infarction was observed with C3aRA treatment relative to vehicle in all cohorts (vehicle: n = 21; acute: n = 24, combined: n = 23, delayed: n = 23) (p<0.01**, p<0.05*) (A). There were no significant reductions in cortical (B) and total infarct volume (C) observed.
Figure 5 Antagonism of the C3aR provides sustained histologic neuroprotection. Infarct volume was determined by integrating serial coronal H&E stained sections. Significantly decreased volume of subcortical infarction was observed with C3aRA treatment relative to vehicle in all cohorts (vehicle: n = 21; acute: n = 24, combined: n = 23, delayed: n = 23) (p<0.01**, p<0.05*) (A). There were no significant reductions in cortical (B) and total infarct volume (C) observed.CC BY · PubMed Central
Figure 6 C3aR antagonism improves neurological function following reperfused stroke. The Morris water maze was used to evaluate navigational memory at 7 days post-stroke. Significant improvement (vehicle: n = 21, acute: n = 24, combined: n = 23, delayed: n = 23) was observed in both acutely and combined-treated mice (p = 0.04* and p = 0.002** respectively) (A). The corner turn test was employed to evaluate post-ischemic sensorimotor function and demonstrated significantly (p = 0.02) improved outcome in the acutely-treated animals (vehicle: n = 25, acute: n = 26, combined: n = 24, delayed: n = 28) (B).
Figure 6 C3aR antagonism improves neurological function following reperfused stroke. The Morris water maze was used to evaluate navigational memory at 7 days post-stroke. Significant improvement (vehicle: n = 21, acute: n = 24, combined: n = 23, delayed: n = 23) was observed in both acutely and combined-treated mice (p = 0.04* and p = 0.002** respectively) (A). The corner turn test was employed to evaluate post-ischemic sensorimotor function and demonstrated significantly (p = 0.02) improved outcome in the acutely-treated animals (vehicle: n = 25, acute: n = 26, combined: n = 24, delayed: n = 28) (B).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 75

Metadata

Authors
Ducruet, A. F., Zacharia, B. E., Sosunov, S. A., Gigante, P. R., Yeh, M. L., Gorski, J. W., Otten, M. L., Hwang, R. Y., DeRosa, P. A., Hickman, Z. L., Sergot, P., & Connolly, E. S.
Affiliations
Columbia University (US)
Corresponding author
Ducruet, Andrew F.
Venue
PLoS ONE
Published
2012-06-26
Volume
7
Issue
6
Pages
e38664
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2058792228
Cited by
75
References
35
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 10 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 6 · 2017: 6 · 2016: 1 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 2
FWCI
3.20
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • American Heart Association
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke (R01NS040409)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords
complement inhibition, cerebral ischemia, endogenous neurogenesis, subventricular zone, T cell infiltration, post-ischemic inflammation, neuroblast proliferation, stroke treatment
MeSH terms
Animals, Anti-Inflammatory Agents, Brain Ischemia, Disease Models, Animal, Inflammation, Male, Mice, Inbred C57BL, Receptors, Complement, T-Lymphocytes, Reperfusion Injury, Complement C3a, Survival Rate, Neuroprotective Agents, Stroke, Mice, Neurogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Complement Inhibition Promotes Endogenous Neurogenesis and Sustained Anti-Inflammatory Neuroprotection following Reperfused Stroke. https://app.cochat.ai/papers/10.1371/journal.pone.0038664
The paper
Ducruet, A. F., Zacharia, B. E., Sosunov, S. A., Gigante, P. R., Yeh, M. L., Gorski, J. W., Otten, M. L., Hwang, R. Y., DeRosa, P. A., Hickman, Z. L., Sergot, P., & Connolly, E. S. (2012). Complement Inhibition Promotes Endogenous Neurogenesis and Sustained Anti-Inflammatory Neuroprotection following Reperfused Stroke. PLoS ONE. https://doi.org/10.1371/journal.pone.0038664

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.